How Big of an Opportunity Do Pfizer and BioNTech Have in Vaccinating Younger Kids?
1/10 12:55
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently reported positive data from a late-stage study of their COVID-19 vaccine in children ages 5 to 11. The companies plan to soon file for Emergency Use Authorization in this age group. In this Motley Fool Live video recorded on...